Figure 3.

CD22 CART^pos and CART^neg eradicate NALM6 leukemia in vitro

(A) Production of IFNγ, IL-17A, tumor necrosis factor α (TNFα), IL-2, IL-4, IL-10, and IL-6 cytokines and IL-8, RANTES, MIG, IP-10, and MCP-1 chemokines by CD22 CART^pos and CART^neg were monitored over 72 h following co-culture with CD22⁺ or CD22^– (CD22^KO) NALM6. Average cytokine concentrations were min/max scaled by the lower and upper detection limits of each cytokine across all samples and divided by the number of cytokines to yield a polyfunctionality index, presented as an average of six individual donors (top). Cumulative concentrations of each cytokine and chemokine are presented (bottom). The ALL patient sample is indicated with an x. (B) In vitro anti-leukemic activity of CD22 CART^pos and CART^neg were monitored against NALM6^WT and NALM6^CD22KO at a 1:1 effector/target ratio, evaluated as a function of GFP expression. Killing indices (left) and killing rates (right) from six individual donors are presented. Statistical significance was calculated using ratio paired t tests; ∗p < 0.05, ∗∗p < 0.01, ∗∗∗∗p<0.0001.